What is 3billion?
Based out of Seoul, South Korea, 3billion is a pioneering gene sequencing company that specializes in rare disease screening technology. The company leverages advanced genomic analysis to identify and diagnose rare genetic disorders, aiming to provide critical insights for both patients and healthcare providers. Its focus on a niche yet vital area of medical technology underscores its strategic importance in the biotechnology sector.
How much funding has 3billion raised?
3billion has raised a total of $291M across 3 funding rounds:
Series A
$268M
Series B
$10M
Series C
$13M
Series A (2018): $268M with participation from The Wells Investment, Korea Development Bank, and JW Assets
Series B (2019): $10M led by The Wells Investment, Korea Development Bank, and JW Assets
Series C (2021): $13M supported by Yuanta Investment, The Wells Investment, Magna Investment, Aventures Investment, Kakao Investment, JW Assets, and KOREA INVESTMENT & SECURITIES
Key Investors in 3billion
Yuanta Investment
Yuanta Investment is a financial firm committed to transparency and investing in companies with high earnings potential, aiming to generate capital gains through corporate growth. They provide thorough due diligence and support to their portfolio companies.
The Wells Investment
The Wells Investment is a venture capital and private equity firm focused on fostering sustainable prosperity by providing capital, management expertise, and networks to promising growth-stage businesses, particularly in bio-healthcare and deep tech.
Magna Investment
Magna Investment is a private investment firm established in 2005, focusing on building sustainable growth and creating lasting impact through strategic investments across various asset classes, including Real Estate, Private Equity, and Venture Capital.
What's next for 3billion?
With the recent major strategic investment, 3billion is poised to accelerate its research and development initiatives, enhance its technological capabilities, and expand its market reach. This capital infusion is expected to fuel the company's growth, enabling it to further solidify its position as a leader in rare disease diagnostics. The company's strategic focus on innovation and its commitment to addressing unmet medical needs suggest a promising future trajectory, potentially leading to further significant milestones and partnerships within the global healthcare ecosystem.
See full 3billion company page
